From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets
Business Case Journal · 12.08.2026 · 33 (1) · 74
DOI: 10.69521/bcj.v33i1.5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Business Case Journal, online erschienen am 12.08.2026. Verfasst von Zachary White und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Novo Nordisk boasted two highly successful pharmaceutical brands, Ozempic and Wegovy. Each brand contained the same active ingredient (semaglutide). However, Ozempic was positioned as a diabetes treatment, while Wegovy was positioned as a weight loss treatment. Both brands faced challenges of building brand equity while competing in a competitive but growing market. The student is ultimately asked to design a plan moving forward amidst the challenges of managing popular brands.
Zitieren
APA
White, Z., Brooks, B., & Cox, S. (2026). From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets. Business Case Journal, 33(1), 74. https://doi.org/10.69521/bcj.v33i1.5
Vancouver
White Z, Brooks B, Cox S. From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets. Business Case Journal. 2026;33(1):74. doi:10.69521/bcj.v33i1.5
BibTeX
@article{White2026,
author = {White, Zachary and Brooks, Bradley and Cox, Steven},
title = {From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets},
journal = {Business Case Journal},
year = {2026},
volume = {33},
number = {1},
pages = {74},
doi = {10.69521/bcj.v33i1.5}
}
EUVIMED